Compound useful for the treatment of degenerative and inflammatory diseases
A novel compound able to inhibit JAK is disclosed, that comprises a compound according to Formula I: or a pharmaceutically acceptable salt thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.
1. A method for the treatment of psoriatic arthritis, comprising:
administering to a subject in need thereof an amount of a compound according to Formula I:
or a pharmaceutically acceptable salt thereof sufficient to effect said treatment.
2. The method according to claim 1 , wherein the compound is administered in combination with one or more further therapeutic agents selected from agents for the treatment of psoriatic arthritis.
3. The method according to claim 2 , wherein the compound is administered in combination with one further therapeutic agent selected from agents for the treatment of psoriatic arthritis.
4. A method for the treatment of psoriatic arthritis, comprising:
administering to a subject in need thereof an amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound according to Formula I:
or a pharmaceutically acceptable salt thereof, sufficient to effect said treatment.
5. A method for the treatment of psoriatic arthritis, comprising:
administering to a subject in need thereof an amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier, a pharmaceutically effective amount of a compound according to Formula I:
or a pharmaceutically acceptable salt thereof, and a further therapeutic agent, sufficient to effect said treatment.
6. The method according to claim 4 , wherein the pharmaceutical composition is administered in combination with one or more further therapeutic agents selected from agents for the treatment of psoriatic arthritis.
7. The method according to claim 6 , wherein the pharmaceutical composition is administered in combination with one further therapeutic agent selected from agents for the treatment of psoriatic arthritis.
8. The method according to claim 5 , wherein the further therapeutic agent is an agent for the treatment of psoriatic arthritis.